This biotech powerhouse could maintain its strength for the long term.

This player's pipeline should keep growth going over the long run.

The company is studying its approved drug for many other indications.

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See more on FBIO.

Vor Biopharma experienced a remarkable morning on December 9, 2025, as shares of the biotech company surged more than 40% in premarket trading. The dramatic rally came after JPMorgan analysts ...

Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the business’ CEO has confirmed. | Japan-based cell therapy company ...

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated ...